Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Update

Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 1,600 shares, a decrease of 33.3% from the September 15th total of 2,400 shares. Based on an average daily volume of 27,300 shares, the short-interest ratio is presently 0.1 days.

Enzon Pharmaceuticals Price Performance

Shares of ENZN traded down $0.01 during mid-day trading on Monday, reaching $0.11. 14,996 shares of the company’s stock traded hands, compared to its average volume of 24,505. The stock has a market cap of $8.16 million, a P/E ratio of 11.00 and a beta of 0.48. The stock’s 50-day moving average is $0.14 and its two-hundred day moving average is $0.13. Enzon Pharmaceuticals has a 12 month low of $0.06 and a 12 month high of $0.24.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs.